

INTERIM FORMULARY UPDATE

The following recommendations, made at the March 27 2009 meeting of the Executive Formulary Committee, are approved:

Product(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Carvedilol	Coreg®	Tablet: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg	Cardiovascular; Beta-Adrenergic Blocking Agents
Guanfacine	Tenex®	Tablet: 1 mg, 2 mg	*Psychotropics; Miscellaneous Psychotropic
Linezolid	Zyvox®	Tablet: 600 mg	#Reserve Category: Antibiotics, Miscellaneous Antibiotic

* Placed in this category based on intended use considered when adding it to Formulary

Reserve Guidelines for use: Patients at TCID or in consultation with an expert in infectious disease

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

The following changes were made to the psychotropic consent list:

- Add desvenlafaxine (Pristiq®) nonformulary to the antidepressant list
- Changed nefazodone (Serzone®) to nonformulary
- Add selegiline (Emsam®) to the monoamine oxidase inhibitor list
- Add lisdexamfetamine (Vyvanse®) nonformulary to the stimulant list
- Add methamphetamine (Desoxyn®) nonformulary to the stimulant list
- Add methylphenidate patch (Daytrana®) nonformulary to the stimulant list
- Add the trade name Metadate CD to the methylphenidate listing
- Remove nonformulary to the guanfacine listing

Approved:



Pharmacy Services Director
DSHS, Hospital Section